Gene transfer into human cord blood-derived CD34+ cells by adeno-associated viral vectors

Experimental Hematology

Volumn 38, Issue 9, 2010, Pages 707-717

  Schuhmann, Natascha K ^a   Pozzoli, Ombretta ^b   Sallach, Jessica ^a   Huber, Anke ^a   Avitabile, Daniele ^c   Perabo, Luca ^a   Rappl, Gunter ^a   Capogrossi, Maurizio C ^c   Hallek, Michael ^a   Pesce, Maurizio ^b   Büning, Hildegard ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; CD34 ANTIGEN; PARVOVIRUS VECTOR; RETINOIC ACID; TRICHOSTATIN A; VERY LATE ACTIVATION ANTIGEN 5;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; SEROTYPE; TRANSGENE; UMBILICAL CORD BLOOD; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS ENTRY;

EID: 77955502649     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.04.016     Document Type: Article

References (83)

1. Segers V.F., Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008, 451:937-942.
2. Abdel-Latif A., Bolli R., Tleyjeh I.M., et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007, 167:989-997.
3. Lipinski M.J., Biondi-Zoccai G.G., Abbate A., et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007, 50:1761-1767.
4. Martin-Rendon E., Brunskill S., Doree C., et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2008, (4):CD006536.
5. Martin-Rendon E., Brunskill S.J., Hyde C.J., Stanworth S.J., Mathur A., Watt S.M. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 2008, 29:1807-1818.
6. Chen J.Z., Zhang F.R., Tao Q.M., Wang X.X., Zhu J.H. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin Sci (Lond) 2004, 107:273-280.
7. Cosentino F., Luscher T.F. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 1998, 32(Suppl 3):S54-S61.
8. Heiss C., Keymel S., Niesler U., Ziemann J., Kelm M., Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol 2005, 45:1441-1448.
9. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348:593-600.
10. Seeger F.H., Zeiher A.M., Dimmeler S. Cell-enhancement strategies for the treatment of ischemic heart disease. Nat Clin Pract Cardiovasc Med 2007, 4(Suppl 1):S110-S113.
11. Seeger F.H., Tonn T., Krzossok N., Zeiher A.M., Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007, 28:766-772.
12. Zemani F., Silvestre J.S., Fauvel-Lafeve F., et al. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 2008, 28:644-650.
13. Asahara T., Kalka C., Isner J.M. Stem cell therapy and gene transfer for regeneration. Gene Ther 2000, 7:451-457.
14. Kobayashi K., Kondo T., Inoue N., et al. Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis. Arterioscler Thromb Vasc Biol 2006, 26:1465-1472.
15. Nabel E.G. Stem cells combined with gene transfer for therapeutic vasculogenesis: magic bullets?. Circulation 2002, 105:672-674.
16. Daniel R., Smith J.A. Integration site selection by retroviral vectors: molecular mechanism and clinical consequences. Hum Gene Ther 2008, 19:557-568.
17. Kohn D.B. Gene therapy for childhood immunological diseases. Bone Marrow Transplant 2008, 41:199-205.
18. Kreppel F., Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008, 16:16-29.
19. Buning H., Perabo L., Coutelle O., Quadt-Humme S., Hallek M. Recent developments in adeno-associated virus vector technology. J Gene Med 2008, 10:717-733.
20. Wu Z., Asokan A., Samulski R.J. adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006, 14:316-327.
21. Bainbridge J.W., Smith A.J., Barker S.S., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358:2231-2239.
22. Christine C.W., Starr P.A., Larson P.S., et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009, 73:1662-1669.
23. Eberling J.L., Jagust W.J., Christine C.W., et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008, 70:1980-1983.
24. Hauswirth W.W., Aleman T.S., Kaushal S., et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008, 19:979-990.
25. Kaplitt M.G., Feigin A., Tang C., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369:2097-2105.
26. Maguire A.M., Simonelli F., Pierce E.A., et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008, 358:2240-2248.
27. Stroes E.S., Nierman M.C., Meulenberg J.J., et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008, 28:2303-2304.
28. Gaipa G., Tilenni M., Straino S., et al. GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy. J Cell Mol Med 2009 Jul 20, [Epub ahead of print].
29. Pesce M., Orlandi A., Iachininoto M.G., et al. Myoendothelial differentiation of human umbilical cord blood-derived stem cells in ischemic limb tissues. Circ Res 2003, 93:e51-62.
30. Asokan A., Hamra J.B., Govindasamy L., Agbandje-McKenna M., Samulski R.J. Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol 2006, 80:8961-8969.
31. Hacker U.T., Wingenfeld L., Kofler D.M., et al. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J Gene Med 2005, 7:1429-1438.
32. Rabinowitz J.E., Rolling F., Li C., et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002, 76:791-801.
33. Xiao X., Li J., Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998, 72:2224-2232.
34. Theiss H.D., Kofler D.M., Buning H., et al. Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotides. Exp Hematol 2003, 31:1223-1229.
35. Timmermans F., Plum J., Yoder M.C., Ingram D.A., Vandekerckhove B., Case J. Endothelial progenitor cells: identity defined?. J Cell Mol Med 2009, 13:87-102.
36. McCarty D.M., Fu H., Monahan P.E., Toulson C.E., Naik P., Samulski R.J. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003, 10:2112-2118.
37. Alexander I.E., Russell D.W., Miller A.D. Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results. Hum Gene Ther 1997, 8:1911-1920.
38. Summerford C., Samulski R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998, 72:1438-1445.
39. Ponnazhagan S., Mukherjee P., Wang X.S., et al. Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. J Virol 1997, 71:8262-8267.
40. Summerford C., Bartlett J.S., Samulski R.J. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999, 5:78-82.
41. Angulo A., Suto C., Heyman R.A., Ghazal P. Characterization of the sequences of the human cytomegalovirus enhancer that mediate differential regulation by natural and synthetic retinoids. Mol Endocrinol 1996, 10:781-793.
42. Gaetano C., Catalano A., Palumbo R., et al. Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. Gene Ther 2000, 7:1624-1630.
43. Case J., Mead L.E., Bessler W.K., et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007, 35:1109-1118.
44. Yoon C.H., Hur J., Park K.W., et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005, 112:1618-1627.
45. Yoder M.C., Mead L.E., Prater D., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809.
46. Urbich C., Heeschen C., Aicher A., Dernbach E., Zeiher A.M., Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003, 108:2511-2516.
47. Rohde E., Malischnik C., Thaler D., et al. Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006, 24:357-367.
48. Rohde E., Bartmann C., Schallmoser K., et al. Immune cells mimic the morphology of endothelial progenitor colonies in vitro. Stem Cells 2007, 25:1746-1752.
49. Gianella A., Guerrini U., Tilenni M., et al. Magnetic resonance imaging of human endothelial progenitors reveals opposite effects on vascular and muscle regeneration into ischaemic tissues. Cardiovasc Res 2010, 85:503-513.
50. Kawamoto A., Losordo D.W. Endothelial progenitor cells for cardiovascular regeneration. Trends Cardiovasc Med 2008, 18:33-37.
51. Liew A., Barry F., O'Brien T. Endothelial progenitor cells: diagnostic and therapeutic considerations. Bioessays 2006, 28:261-270.
52. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001, 89:E1-E7.
53. Kawamoto A., Iwasaki H., Kusano K., et al. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 2006, 114:2163-2169.
54. Losordo D.W., Schatz R.A., White C.J., et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 2007, 115:3165-3172.
55. Sekiguchi H., Ii M., Losordo D.W. The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J Cell Physiol 2009, 219:235-242.
56. Carmona G., Chavakis E., Koehl U., Zeiher A.M., Dimmeler S. Activation of Epac stimulates integrin-dependent homing of progenitor cells. Blood 2008, 111:2640-2646.
57. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001, 108:391-397.
58. Marchetti V., Menghini R., Rizza S., et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006, 55:2231-2237.
59. Gadau S., Emanueli C., Van Linthout S., et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006, 49:405-420.
60. Krankel N., Katare R.G., Siragusa M., et al. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res 2008, 103:1335-1343.
61. Iwaguro H., Yamaguchi J., Kalka C., et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002, 105:732-738.
62. Burba I., Devanna P., Pesce M. When cells become a drug. endothelial progenitor cells for cardiovascular therapy: aims and reality. Recent Pat Cardiovasc Drug Discov 2010, 5:1-10.
63. Iwaguro H., Asahara T. Endothelial progenitor cell culture and gene transfer. Methods Mol Med 2005, 112:239-247.
64. Koponen J.K., Kekarainen T., E Heinonen S., et al. Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. Mol Ther 2007, 15:2172-2177.
65. Yotnda P., Onishi H., Heslop H.E., et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther 2001, 8:930-937.
66. Grimm D., Kay M.A. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003, 3:281-304.
67. Handa A., Muramatsu S., Qiu J., Mizukami H., Brown K.E. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J Gen Virol 2000, 81:2077-2084.
68. Bantel-Schaal U., Delius H., Schmidt R., zur Hausen H. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J Virol 1999, 73:939-947.
69. Kaludov N., Brown K.E., Walters R.W., Zabner J., Chiorini J.A. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001, 75:6884-6893.
70. Di Pasquale G., Davidson B.L., Stein C.S., et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003, 9:1306-1312.
71. Maina N., Han Z., Li X., et al. Recombinant self-complementary adeno-associated virus serotype vector-mediated hematopoietic stem cell transduction and lineage-restricted, long-term transgene expression in a murine serial bone marrow transplantation model. Hum Gene Ther 2008, 19:376-383.
72. Veldwijk M.R., Sellner L., Stiefelhagen M., et al. Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34(+) peripheral blood progenitor cells. Cytotherapy 2010, 12:107-112.
73. McCarty D.M. Self-complementary AAV vectors; advances and applications. Mol Ther 2008, 16:1648-1656.
74. Zhong L., Li W., Li Y., et al. Evaluation of primitive murine hematopoietic stem and progenitor cell transduction in vitro and in vivo by recombinant adeno-associated virus vector serotypes 1 through 5. Hum Gene Ther 2006, 17:321-333.
75. Zhong L., Li W., Yang Z., et al. Impaired nuclear transport and uncoating limit recombinant adeno-associated virus 2 vector-mediated transduction of primary murine hematopoietic cells. Hum Gene Ther 2004, 15:1207-1218.
76. Chatterjee S., Li W., Wong C.A., et al. Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood 1999, 93:1882-1894.
77. Goodman S., Xiao X., Donahue R.E., et al. Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood 1994, 84:1492-1500.
78. Zhou S.Z., Cooper S., Kang L.Y., et al. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med 1994, 179:1867-1875.
79. Ferrari F.K., Samulski T., Shenk T., Samulski R.J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996, 70:3227-3234.
80. Fisher K.J., Gao G.P., Weitzman M.D., DeMatteo R., Burda J.F., Wilson J.M. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996, 70:520-532.
81. Nathwani A.C., Hanawa H., Vandergriff J., Kelly P., Vanin E.F., Nienhuis A.W. Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. Gene Ther 2000, 7:183-195.
82. Sanlioglu S., Benson P.K., Yang J., Atkinson E.M., Reynolds T., Engelhardt J.F. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol 2000, 74:9184-9196.
83. Minucci S., Pelicci P.G. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 1999, 10:215-225.